Arunima Mamidi, MD | |
5 Plainsboro Road, Suite 360, Plainsboro, NJ 08536 | |
(609) 750-0011 | |
(609) 750-0022 |
Full Name | Arunima Mamidi |
---|---|
Gender | Female |
Speciality | Infectious Disease |
Experience | 32 Years |
Location | 5 Plainsboro Road, Plainsboro, New Jersey |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1730196478 | NPI | - | NPPES |
J31841 | Other | HEALTHNET | |
7947607 | Medicaid | NJ | |
2227114001 | Other | KEYSTONE | |
60006502 | Other | HORIZON NJ HEALTH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | MA068633 (New Jersey) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Medical Center Of Princeton At Plainsboro | Plainsboro, NJ | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mamidi Arunima Md Llc | 5698822922 | 4 |
News Archive
The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.
BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it has entered into a licence agreement with Octapharma (Lachen, Switzerland), an independent, global provider of human proteins for life-threatening diseases.
Bristol-Myers Squibb Company and Solvay Pharmaceuticals today announced that the companies have entered into a worldwide agreement for the Solvay compound SLV319, which is currently in Phase I development with potential for use in treating obesity and other metabolic disorders.
Alli which is produced by GlaxoSmithKline will be available to consumers in America next week following a 150 million dollar advertising campaign to promote the non-prescription drug.
› Verified 5 days ago
Entity Name | Mamidi Arunima Md Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1841207578 PECOS PAC ID: 5698822922 Enrollment ID: O20090402000400 |
News Archive
The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.
BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it has entered into a licence agreement with Octapharma (Lachen, Switzerland), an independent, global provider of human proteins for life-threatening diseases.
Bristol-Myers Squibb Company and Solvay Pharmaceuticals today announced that the companies have entered into a worldwide agreement for the Solvay compound SLV319, which is currently in Phase I development with potential for use in treating obesity and other metabolic disorders.
Alli which is produced by GlaxoSmithKline will be available to consumers in America next week following a 150 million dollar advertising campaign to promote the non-prescription drug.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Arunima Mamidi, MD Po Box 145, Blawenburg, NJ 08504 Ph: (609) 371-4666 | Arunima Mamidi, MD 5 Plainsboro Road, Suite 360, Plainsboro, NJ 08536 Ph: (609) 750-0011 |
News Archive
The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.
BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it has entered into a licence agreement with Octapharma (Lachen, Switzerland), an independent, global provider of human proteins for life-threatening diseases.
Bristol-Myers Squibb Company and Solvay Pharmaceuticals today announced that the companies have entered into a worldwide agreement for the Solvay compound SLV319, which is currently in Phase I development with potential for use in treating obesity and other metabolic disorders.
Alli which is produced by GlaxoSmithKline will be available to consumers in America next week following a 150 million dollar advertising campaign to promote the non-prescription drug.
› Verified 5 days ago
Catherine Chen, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Plainsboro Rd, Plainsboro, NJ 08536 Phone: 609-853-6049 Fax: 609-853-7221 | |
Arjun Fung-janardhan, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Plainsboro Rd, Plainsboro, NJ 08536 Phone: 609-853-6049 | |
Mrs. Silky Sharma, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Plainsboro Rd, Plainsboro, NJ 08536 Phone: 609-853-5600 | |
Dr. Ahmed Mirza, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 666 Plainsboro Rd, Suite 1318, Plainsboro, NJ 08536 Phone: 732-266-3733 | |
Dr. Lloyd Antoine Webster Jr., M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Plainsboro Rd, Plainsboro, NJ 08536 Phone: 609-853-6049 Fax: 609-853-7221 | |
Dr. Ramy Sedhom, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5 Plainsboro Rd Ste 540, Plainsboro, NJ 08536 Phone: 609-853-6590 Fax: 609-853-6581 | |
Dr. Matthew Sandel, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5 Plainsboro Rd Ste 350, Plainsboro, NJ 08536 Phone: 609-853-6049 Fax: 609-853-7221 |